INTRODUCTION study was designed to test the ability of a new
Aspirin is frequently used as an antiplatelet TSI, U-63557A [24] , to enhance the patency agent in an attempt to improve the patency rate of autogenous vein grafts in the canine rate of small diameter vascular grafts. Such femoral artery circulation. The in vivo procyclooxygenase inhibitors, however, have the duction of TXBz (the stable metabolite of theoretical disadvantage of inhibiting prosta-TXAz) and platelet accumulation on vein graft cyclin (PGIz) production in addition to surfaces were measured to correlate with the thromboxane A2 (TXAz) synthesis. This criteffect of U-63557A on graft patency.
icism has stimulated the development of selective thromboxane synthetase inhibitors METHODS (TSIs) which may increase PGIz production by redirecting endoperoxide precursors that Graft patency determination. Twenty-five accumulate during TXAz inhibition [ll] . adult mongrel dogs of both sexes (18-30 kg) Since autogenous vein grafts retain the ability were divided into control (n = 15) and treatto synthesize PGIl [6] , we hypothesized that ment (n = 10) groups. Treatment dogs re-TSI treatment would be more beneficial for ceived U-63557A [sodium 5-(3'-pyridinylthese grafts than for prosthetic grafts. This methyl)benzofuran-2-carboxylate 1, an orally active TSI, 10 mg/kg po q8 hr beginning 24 ' To whom reprint requests should be addressed: De- hr prior to surgery and continuing for the 6- no treatment. After iv thiamylal induction, 297 0022-4804/86 $1 SO dogs were anesthetized with halothane, nitrous oxide, and oxygen inhalation for graft implantation. Using sterile technique, the femoral and carotid arteries and external jugular veins were exposed bilaterally. Both jugular veins were harvested to provide an 8-cm segment for superficial femoral artery (SFA) implantation in all dogs; a 3-cm segment for common carotid artery implantation in six treated and eight control dogs; and a 2-cm segment for baseline TXBz assay in all dogs. One of the jugular veins was removed for immediate implantation without storage, distention, or irrigation, while the contralateral jugular vein was placed in 37°C normal saline storage for 1 hr in an attempt to induce endothelial damage. Vein grafts placed in the femoral location were reversed and anastomosed in an end-to-side fashion using continuous 6-O polypropylene suture with spatulation of the anastomoses, from the proximal SFA, immediately distal to the profunda branch, to a point in the SFA 8 cm distally. A 5 Fr ligature was placed around the distal SFA in order to reproducibly restrict graft outflow. The mid portion of the SFA was ligated to completely divert blood flow through the vein graft. Vein grafts placed in the common carotid arteries were reversed and anastomosed in an end-to-end fashion using continuous 6-O polypropylene suture. Femoral and carotid vein grafts were simultaneously implanted by two operating teams to ensure equivalent graft treatment and storage time. The jugular vein removed for immediate use (normal vein) was implanted on one side in both the carotid and femoral locations, while the jugular vein selected for I-hr warm saline storage (stored vein) was implanted into the contralateral carotid and femoral artery locations.
A midline, lower abdominal incision was used to expose the middle sacral artery. An INFUSAID injection port was implanted in a subcutaneous pocket in the lower abdomen and its Silastic catheter placed just inside the infrarenal aorta via the middle sacral artery for subsequent arteriography. The surgical incisions were closed and the dogs recovered from anesthesia. Normal saline ( 1 -1.5 1 iv) was administered during the 3-hr operative procedure, and penicillin-G plus streptomycin were administered im preoperatively and on Postoperative Days 1 and 2.
Arteriograms were obtained under brief thiamylal sodium anesthesia at 24 hr and at 1, 2, 4, and 6 weeks postoperatively. Renografin-76 (20 ml) was injected into the infrarenal aorta via the subcutaneous injection port and a single timed X-ray exposure was made to visualize the femoral artery grafts.
Graft platelet deposition. The subset of dogs that received carotid vein grafts underwent indium-1 11 oxine platelet labeling on Postoperative Day 6. Platelet labeling was performed using a modification of the technique of Thakur et al. [23] . Venous blood was drawn through a large bore needle into plastic syringes containing two different anticoagulants (36 ml blood4 ml acid citrate dextrose (ACD); 18 ml blood2 ml 3.8% sodium citrate). After centrifugation of these separate samples at 2008 for 10 min, platelet-rich plasma (PRP) and platelet-poor plasma (PPP) were isolated. Both ACD and sodium citrate-prepared PRP were then centrifuged at 1OOg for 10 min. Traces of ACD plasma in the platelet button were eliminated by twice layering and removing 2 ml of modified Tyrodes solution (MTS) [23] at 37°C. Platelet pellets were then suspended in 4 ml MTS at 37°C and 500 mCi (0.5 ml) of "'In oxine (Amersham, saline solution) was added dropwise to the platelet suspension. Platelets were then incubated at 37°C for 10 min, and 4 ml of ACD-prepared PPP was added prior to 7-min centrifugation at 1 OOOg to remove any unbound oxine. The labeled platelets were finally resuspended in 4 ml of sodium citrate-prepared PPP for iv reinjection into the animal.
One day later, the dogs were reanesthetized (thiamylal sodium), the neck incisions reexplored, and the carotid vein grafts harvested to include a l-cm segment of proximal and distal native carotid artery. After removal, the graft segments and adjacent carotid artery were gently flushed with normal saline to remove any contained blood. The grafts were then di-vided into five segments, 1 cm in length, consisting of proximal and distal native carotid artery, proximal and distal anastomoses, and central vein graft. Each sample was weighed and subsequently counted for ' ' ' In activity in a gamma well counter. A sample of blood was removed at the time of carotid graft harvest and also counted to determine the "I In activity of circulating platelets. Since graft and artery diameters were uniform in these dogs, small variations in the length of the counted graft and artery segments were normalized by dividing the counts per segment by the segment weight. Platelet deposition was expressed as the ratio of the "'In counts per gram of graft (artery) segment divided by the counts per 100 ~1 of circulating blood.
Thromboxane production. Luminal vein graft TXBz production was measured using a technique suggested by Eldor et al. [ 121. The segment of vein to be analyzed was incised longitudinally to expose the endothelial surface, which was gently but thoroughly irrigated with Tris buffer (pH 7.4). The vein segment was then clamped in a plastic template which exposed a 0.79~cm* endothelial surface area to a 2-cm-deep circular well which was filled with 1 ml Tris buffer at 37°C. The vein graft was incubated in this template for 30 min at 37"C, after which the buffer was removed and frozen for subsequent TXB2 radioimmunoassay [ 131. Vein graft TXB2 production was measured at the time of graft implantation from both immediately implanted and warm saline-stored graft segments, as well as from vein grafts harvested after 1 week of carotid implantation.
The central portion of the carotid vein graft was used for this determination prior to the determination of its "'In activity.
Statistical analysis. Vein graft patency was analyzed by product moment actuarial technique with significant differences determined by the Wilcoxon test. Patency at individual time points for TSI-treated and control dogs was tested by the Fisher exact test for independent samples, while differences between immediately implanted and warm salinestored grafts were tested by the McNemar test for paired data [9] . TXB2 production and " 'In platelet deposition were compared between treatment groups by the Mann-Whitney test and within treatment groups by the Wilcoxon sign ranks test (all two-tail analyses) [9] . Correlation between graft patency, TXB2 production, and platelet deposition was measured by the Spearman rank correlation coefficient.
RESULTS
In this canine model, autogenous jugular vein grafts placed in the femoral artery location demonstrated 6-week cumulative patency rates of 53 to 70%. Most graft occlusions occurred during the first 2 weeks of implantation, with only 2 of 50 grafts occluding between 2 and 6 weeks (Fig. 1) . TSI treatment appeared to improve the patency of both normal and warm saline stored vein grafts when compared with untreated control dogs, although actuarial analysis of these survival curves did not demonstrate statistical significance (Wilcoxon test). The effect of TSI was most apparent 1 week after graft implantation when normal vein grafts in control dogs demonstrated a 27% lower patency than in TSI-treated dogs (P = 0.13, Fisher exact test, Table 1 ). This nearly significant difference also existed for saline stored grafts, which had a 27% lower l-week patency in control dogs compared with TSItreated dogs (P = 0.20, Fisher exact test, Table  1 on graft patency, warm saline storage reduced l-week graft patency by 20% in both TSItreated and control dogs. These differences, which approached statistical significance at 1
Graft and treatment subgroups were combined to evaluate the effect of TSI treatment week, were nearly eliminated by 6 weeks, when on both normal and saline-stored vein grafts (n = 30 control, n = 20 treatment), as well as normal and saline-stored veins had compathe effect of warm saline storage on both control and TSI treated dogs (n = 25 normal, n rable patency rates (Table 1) Vein graft TXB2 production was three to seven times lower in TSI-treated dogs than in control dogs when assayed at implantation and at 1 week postoperatively (Table 2 ). These reductions were highly significant for both normal and warm saline-stored grafts. TXB2 production increased three-to sevenfold in all vein grafts removed at 1 week compared with the same grafts at implantation. There was no significant difference in TXB2 production, how-' ' 'In-labeled platelet deposition occurred predominantly at the proximal and distal caever, between normal and saline-stored vein rotid vein graft anastomoses. There was no significant difference in platelet deposition begrafts at implantation or at 1 week postopertween the proximal and distal carotid artery segments and the midportion of normal jugular vein grafts in control dogs (Table 3) . Sigatively (Table 2) .
nificantly increased platelet deposition did oc- cur at both anastomoses. Platelet deposition was two to four times greater in saline-stored vein grafts in the same control dogs, at both the anastomoses and the vein grail itself (Table  3) . Dogs treated with TSI also demonstrated increased platelet deposition at the anastomoses, but also in the vein graft itself, when compared with proximal or distal artery segments. This enhanced platelet accumulation in normal vein grafts of TSI-treated dogs was significantly greater than the mimimal deposition seen in control dogs (P < 0.02, MannWhitney test). No other significant differences in platelet deposition existed between control and TSI treated animals. As with control dogs, saline-stored vein grafts demonstrated increased platelet deposition in both the graft and the anastomoses when compared with proximal or distal native artery (Table 3) .
There was no correlation (rS < 0.2) between platelet deposition (vein graft or anastomoses) and TXB2 production at the time of carotid vein graft harvest. Furthermore, there was no correlation between vein graft TXB2 production or platelet deposition and l-or 6-week patency of comparably treated femoral artery grafts in the same animals.
DISCUSSION
In contrast to aspirin and other cyclooxygenase inhibitors, selective inhibition of TXA2 synthetase has the theoretical advantage of preserving or increasing PGIl production. Accumulated endoperoxides resulting from TXA2 inhibition appear to be redirected to enhance PGI* synthesis when PGIz synthetase is available [8, 10, (often combined with dipyridamole) has improved aortocoronary vein graft patency in some clinical trials and has reduced vein graft anastomotic intimal fibroplasia in experimental models [6, 201 . In contrast, aspirin treatment in rabbit endothelial injury models inhibited endothelial healing, enhanced platelet accumulation, and reduced PGIz production [3, 41. Treatment of injured rabbit endothelium with TSI, however, reduced platelet deposition and enhanced PG12 synthesis [ 10, 16, 2 11. Furthermore, aspirin-dipyridamole did not increase the patency rate of lower extremity autogenous vein grafts in humans [ 191. Since vein graft occlusion remains a significant clinical problem, the above considerations suggested our study of the effect of selective TXA2 inhibition on vein graft patency.
Although TSI caused a marked reduction of TXB2 production in our study, its ability to improve vein graft patency was only modest. Furthermore, even though improved early graft patency was seen in TSI-treated dogs, no corresponding reduction in graft-platelet deposition was demonstrated. Since vein grafts do not accumulate sufficient ' ' 'In-labeled platelets for external gamma camera imaging, it was necessary to remove vein grafts to measure platelet deposition in a well counter. This prevented the measurement of graft patency and platelet deposition in the same graft and led to the use of carotid and femoral artery sites in our model. In retrospect, differences in anastomotic technique, graft length, and blood flow rate might have caused predictable differences in platelet deposition between femoral and carotid artery grafts. Although we did not measure graft flow rates, femoral outflow stenosis almost certainly caused significantly lower graft blood flow in the femoral than in the carotid location. Since lower flow rates increase platelet graft deposition [7] , measurement of platelet deposition in the femoral grafts themselves might have correlated better with early improved femoral graft patency in TSI-treated dogs. These results, therefore, should not be interpreted as disproving a relationship between TSI effects on graft patency and a potential anti-platelet mechanism.
Our finding of improved early vein graft patency after TSI treatment is supported by a recent report of Bergquist et al. [2] . These investigators demonstrated that dazoxiben, an imidozole-derived TSI, improved the patency of human umbilical vein grafts after 4 hr of ex viva perfusion in sheep. Decreased platelet deposition and thrombus weight were associated with decreased TXB2 production. Dazoxiben and other TSIs have also been shown to reduce platelet adhesion on endothelium damaged rabbit arteries and to reduce TXB2 but increase PGIz production [ 10, 2 11. A significant effect of TSI treatment was not seen with Dacron grafts, however, where dazoxiben failed to reduce platelet deposition in an ex viva perfusion circuit or in baboon A-V shunts, despite reduced TXBz production [ 14, 171. These observations suggest that endogenous PG12 production, not present in prosthetic grafts, may be essential for TSI efficacy. This has been demonstrated in a canine coronary artery stenosis model in which effective TSI prevention of platelet aggregation was blocked by cyclooxygenase inhibition that prevented PG12 production [ 1, 151. U-63557A, the TSI used in this study, has been shown to significantly reduce TXBP production in dogs, monkeys, and humans without tachyphylaxis after 14 days of oral administration [ 151. A dose of 10 mg/kg markedly reduced TXB2 production in dogs for 4 to 6 hr [24] . Recent experience in our laboratory suggests that a larger dose of U-63557A might have had more beneficial effects in this study.
Vein graft storage in 37°C saline was used in our study to produce a mild endothelial injury analogous to some clinical settings. LoGerfo et al. reported that such storage resulted in early endothelial disruption and platelet-leukocyte adhesion, with subsequent medial thickening [ 181. Although we did not examine these morphologic changes, warm saline storage was associated with reduced vein graft patency and increased platelet accumulation 1 week after implantation, during the time when endothelial injury exists, according to LoGerfo et al. Elimination of the saline storage effect on 4-to 6-week graft patency corresponds to the time course of endothelial healing after this degree of vein injury [ 181. The basis for increased TXB2 production after 1 week of vein graft implantation was not specifically investigated in this study. We speculate that this increased production may have resulted from increased luminal accumulation of platelets, monocytes, and leukocytes during the first postoperative week that were not present when vein grafts were implanted. Although arteries and veins have been shown to synthesize TXA2 in addition to their more predominant PGIz production [22] , electron microscopy of the vein graft luminal surface would be necessary to exclude a major TXA;! contribution from adherent blood elements.
The use of femoral artery outflow stenosis to reduce autogenous vein graft patency resulted in a 6-week graft patency rate of 53 to 58% in control dogs. Since no grafts occluded between 4 and 6 weeks, this appears to be a practical model to investigate vein graft patency in a 4-week study in dogs. Such a technique is necessary since unrestricted flow through canine autogenous vein grafts nearly always results in 100% long-term patency, making such an animal model impractical for a study with graft occlusion as the endpoint.
Although it is generally accepted that platelet-graft interaction is an important contributor to arterial graft failure, it is equally clear that many factors influence early and late graft patency. Since we do not yet have data concerning the ability of aspirin or other cyclooxygenase inhibitors to improve the patency of vein grafts in this particular animal model, it is difficult to judge the significance of the improvement seen with TSI in this report. The ability of TSI to improve early vein graft patency, during the period of maximal, but transient endothelial injury and decreased PGIz production, however, might be important. These results should stimulate a comparison of the chronic effects of both TSI and aspirin on graft patency and platelet deposition in an appropriate animal model.
